NCI renews UChicago’s CCC designation

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.

November 22, 2024

Vol.50 No.44

White House

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

President-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to the post of secretary of the Department of Health and Human Services, placing the vaccine skeptic in charge of a vast empire of research, engineering, regulatory, and health care agencies.

NCI renews IU Simon Comprehensive Cancer Center’s designation

NCI renewed the Comprehensive Cancer Center designation to the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, awarding it a five-year, $14.2 million grant.

November 15, 2024

Vol.50 No.43

In Brief

UChicago receives $75M from AbbVie Foundation for construction of the cancer care and research pavilion

UChicago Medicine received a $75 million donation from the AbbVie Foundation, a nonprofit focused on advancing health equity, to help fund the construction of the new cancer care and research pavilion.

November 01, 2024

Vol.50 No.41

Clinical

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.

October 25, 2024

Vol.50 No.40

By Claire Marie Porter

Clinical Roundup

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.

October 25, 2024

Vol.50 No.40

NCI renews UChicago’s CCC designation

YOU MAY BE INTERESTED IN

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

NCI renews IU Simon Comprehensive Cancer Center’s designation

UChicago receives $75M from AbbVie Foundation for construction of the cancer care and research pavilion

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Renew today!

Subscriber content

Never miss an issue!

Login